secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001104659-24-073372
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron shareholders elect directors, approve executive compensation at 2024 annual meeting
--------------------------------------------------------------------------------

- Class III directors elected: N.A. Coles, K. Guarini, A.F. Ryan, G.L. Sing; Class II director D.P. Schenkein elected.
- Ratification of PwC as auditor for FY2024: 111.4M for, 5.3M against, 60.6K abstain.
- Advisory vote on executive compensation passed: 106.7M for, 5.6M against, 207.5K abstain, 4.2M broker non-votes.
- Non-binding shareholder proposal requesting simple majority voting approved: 85.9M for, 26.4M against, 188.7K abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465924073372/0001104659-24-073372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465924073372/tm2417559d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-073372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer